Encouragingly, ACC and FAS inhibitors were processed into clinical trials for treatment of patients with NAFLD (Loomba et al., 2018; Syed-Abdul et al., 2020). Here, FAS is linked to metabolic dysfunction-associated steatotic liver disease.